Allergy Therapeutics - Allergy Therapeutics to present at EAACI 2026
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company" or "Group")
Allergy Therapeutics to present pollen and food allergy research data
and host symposium at the EAACI Congress 2026
The EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology. The Academy is an association of more than 16,000 clinicians, researchers and allied health professionals from 124 countries, dedicated to improving the health of people affected by allergic diseases.
Allergy Therapeutics will present 15 posters and oral presentations at the conference, including:
· Data from the Group's Phase I/IIa PROTECT trial of VLP Peanut, the Group's innovative, short-course peanut allergy immunotherapy candidate. The PROTECT trial met the primary endpoint, demonstrating a benign safety profile of VLP Peanut, with a strong dose-response in immunomodulating tolerogenic immune responses induced confirming clinical proof of concept.
· Blinded safety data from the first year of the Company's G308 Phase III trial evaluating the short- and long-term efficacy and safety of Grass MATA MPL in a paediatric population with grass-induced seasonal allergic rhinitis and rhinoconjunctivitis, demonstrating a benign safety profile in the first year of treatment and a low trial discontinuation rate.
The Company will also host a symposium at the EAACI Congress today from 15:00-16:00 TRT, co-chaired by Dr.
In addition, the EAACI Early Career Research Award, supported by Allergy Therapeutics, will be presented to this year's recipient,
"Data from our Phase I/IIa PROTECT trial of VLP Peanut have confirmed a strong safety and tolerability profile of this novel immunotherapy candidate while also demonstrating clinical proof of concept, and we are continuing our preparations for the Group's Phase IIb trial. Clinical progress with Grass MATA MPL has continued following regulatory approval of the product in
"We look forward to discussing our progress with colleagues at the conference and continuing our mission to deliver innovative, disease-modifying therapies for allergy sufferers worldwide."
The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website.
No new material price sensitive information will be disclosed on Allergy Therapeutics at the EAACI Congress 2026.
For further information, please contact:
Allergy Therapeutics
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
+44 (0)20 7220 0500
ICR Healthcare
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE